<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071655</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-09-01(ML25052)</org_study_id>
    <secondary_id>2009-012562-31</secondary_id>
    <nct_id>NCT01071655</nct_id>
  </id_info>
  <brief_title>Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer</brief_title>
  <acronym>SETICC</acronym>
  <official_title>Selecting Treatment in Colorectal Cancer: Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3'UTR and ERCC1-118 to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the capecitabine or&#xD;
      5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be&#xD;
      combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2010-2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of patients whose disease becomes resectable</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of KRAS status as a molecular marker</measure>
    <time_frame>2010-2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with zero favorable genotype: BVZ + XELIRI.&#xD;
Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.&#xD;
Patients with two favorable genotypes : BVZ + FUOX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BVZ + XELOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX</intervention_name>
    <description>BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1&#xD;
BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1&#xD;
BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly&#xD;
BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BVZ+XELOX</intervention_name>
    <description>BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent signed&#xD;
&#xD;
          -  Histological or citological adenocarcinoma confirmation carcinoma on the colon or&#xD;
             colorectal metastatic or relapsed patients with adenocarcinoma of colon or recto,&#xD;
             confirmed histologically with metastatic disease&#xD;
&#xD;
          -  measurable disease (following RECIST criteria)&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  older or equal 18 years old&#xD;
&#xD;
          -  life expectancy superior to 3 months&#xD;
&#xD;
          -  Adequate or moderate renal function: renal function (Creatinine clearance &gt; 30mL/min),&#xD;
             based on Cockroff - Gault.&#xD;
&#xD;
          -  Potential fertile women negative pregnancy test in serum or urine, 10 days prior the&#xD;
             first study dose given&#xD;
&#xD;
          -  Use an adequate contraceptive method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated previously with Bevacizumab&#xD;
&#xD;
          -  Non measurable lesion as only disease evidence&#xD;
&#xD;
          -  Previous chemotherapy treatment for adjuvant or neoadjuvant disease (no metastatic&#xD;
             (M0), or immunotherapy active/passive for the advance or metastatic disease. It is&#xD;
             permitted the adjuvant or neoadjuvant treatment it is has finished at least 6 months&#xD;
             before the initiation of the study drug.If the patient has received an adjuvant&#xD;
             treatment previously the patient cannot participate if disease progression has been&#xD;
             confirmed during the treatment or on the 6 months later&#xD;
&#xD;
          -  Prior radiotherapy is allowed if it has not been administered in the target lesions&#xD;
             selected for this study, unless progression of said lesions in the irradiated field is&#xD;
             documented, and as long as treatment has concluded at least 4 weeks before beginning&#xD;
             the study.&#xD;
&#xD;
          -  Prior surgical treatment of the disease in stage IV is allowed&#xD;
&#xD;
          -  Functional dependency&#xD;
&#xD;
          -  Previous serious adverse events or unexpected to fluoropyrimidine treatment and /o&#xD;
             patients with proved deficit in dehidropirimidin dehydrogenase (DPD)&#xD;
&#xD;
          -  Patients classified as &quot;weak or fragile&quot;&#xD;
&#xD;
          -  Cardiac concomitant present: Symptomatic auriculoventricular arrhythmia history, and /&#xD;
             cardiac arrhythmias requiring medication or peripheral vascular disease, grade II or&#xD;
             higher. Furthermore, those patients who have had a myocardial infarction in the year&#xD;
             prior to beginning the treatment of the study will be excluded.&#xD;
&#xD;
          -  History of another neoplastic disease during the last five years, with the exception&#xD;
             of cured basal cell carcinoma of the skin and cervical carcinoma in situ.&#xD;
&#xD;
          -  History or indications of CNS disease in the physical examination.&#xD;
&#xD;
          -  History of psychiatric disability that the investigator considers clinically&#xD;
             significant, which prevents the patient from granting the informed consent or&#xD;
             interferes with compliance of taking the oral medication.&#xD;
&#xD;
          -  Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular&#xD;
             disease: CVA/stoke (≤ 6 months prior to randomisation), myocardial infarction (≤ 6&#xD;
             months prior to randomisation), unstable angina, New York Heart Association (NYHA,)&#xD;
             Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring&#xD;
             medication.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome&#xD;
             or inability to take oral medication.&#xD;
&#xD;
          -  Patients subjected to organ allograft who require immunosuppressive treatment.&#xD;
&#xD;
          -  Severe, non-cicatrized osseous fractures, wounds or ulcers&#xD;
&#xD;
          -  Indications of hemorrhagic diathesis or coagulopathy.&#xD;
&#xD;
          -  Severe, uncontrolled intercurrent infections or other severe, uncontrolled concomitant&#xD;
             diseases.&#xD;
&#xD;
          -  Any of the following laboratory values:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1.5 x 109/l&#xD;
&#xD;
               2. Platelet count &lt; 100 x 109/l&#xD;
&#xD;
               3. Hemoglobin &lt; 10 g/dl (it can be transfused to maintain or exceed this level)&#xD;
&#xD;
               4. International Normalized Ratio (INR) &gt; 1.5&#xD;
&#xD;
               5. Total bilirubin &gt; 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               6. ALAT, ASAT &gt; 2.5 x ULN or &gt; 5 x (ULN) in the case of hepatic metastases&#xD;
&#xD;
               7. Alkaline phosphatase &gt; 2.5 x ULN or &gt; 5 x ULN in the case of hepatic metastases&#xD;
                  or &gt; 10 x ULN in the case of osseous metastases.&#xD;
&#xD;
          -  Patients subjected to a major surgical procedure, open biopsy or who have had&#xD;
             significant traumatic lesions within the 28 days prior to beginning the treatment of&#xD;
             the study or in whom it is foreseen that a major surgical procedure will be necessary&#xD;
             during the course of the study; fine-needle aspiration within the 7 days prior to&#xD;
             beginning the treatment of the study.&#xD;
&#xD;
          -  Current or recent use (within the 10 days prior to beginning the treatment of the&#xD;
             study) of oral or parenteral anticoagulants at complete doses or thrombolytic agents.&#xD;
             The use of low doses of warfarin is allowed, with an International Normalized Ratio&#xD;
             [INR] of &lt; 1.5.&#xD;
&#xD;
          -  Daily chronic treatment with high doses of aspirin (&gt; 325 mg/day) or non-steroid&#xD;
             anti-inflammatory medications (which inhibit the platelet function at doses used for&#xD;
             treating chronic inflammatory diseases).&#xD;
&#xD;
          -  Patients who have received any drug or agent/procedure under research, i.e., who have&#xD;
             participated in another clinical trial during the 4 weeks prior to beginning the&#xD;
             treatment with the medications of the study.&#xD;
&#xD;
          -  Pregnancy or lactating woman. Woman with reproductive potential unless using an&#xD;
             effective method of contraception (Postmenopausal woman must have been amenorrheic&#xD;
             during at least 12 months).&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or excipients of the Bevacizumab or&#xD;
             to Chinese hamster ovary cell products or to other recombinant human or humanised&#xD;
             antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Abad</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Català d'Oncologia.Hospital Universitari Germans Trias i Pujol. Badalona. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 15, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>5FU</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

